of abdominal distention, vaginal bleeding, and loss of appetite. Ultrasonography revealed bilaterally enlarged ovaries (right 13x8x8 cm, left 12x10x9 cm) with multiple cystic and solid lesions and intra-abdominal ascites. The CA-125 level was 2,340 U/mL and the other tumor markers were within the normal range. Subsequently, a diagnostic laparoscopy was performed to evaluate operability of the patient as she had large bulky masses on ultrasonography. The laparoscopy revealed massive ascites, enlarged ovaries, and multiple diaphragmatic and peritoneal implants, along with an omental cake, and multiple biopsies were taken from the ovaries, omental cake, and peritoneal implants. There were 3 ports at the umbilicus (10 mm) and bilateral inguinal areas (both 5 mm), and the harvesting port was the left inguinal one. The pathological assessment revealed serous papillary ova rian cancer and multiple metastases to the peritoneal and serosal surfaces. Subsequently, neoadjuvant chemotherapy comprising cisplatinum (75 mg/m 2 ) and paclitaxel (175 mg/m 2 ) for 4 courses was given. CA-125 levels were measured as 1,999 U/ mL, 944 U/mL, 368 U/mL and 160 U/mL at the chemotherapy courses, respectively. A subcutaneous, 2x1 cm diameter nodule was noticed on the 3rd neoadjuvant chemo therapy course, 47 days after the laparoscopic procedure, regardless of treatment. Subsequent to the 4th neoadjuvant chemotherapy course, primary debulking surgery including excision of portsite metastasis was performed, and the residual tumor size was <1 cm. The pathological assessment revealed poorly differented serous papillary ovarian cancer with invasion of bilateral ovarian surfaces, parametrium, serosal surfaces of tubes, uterus and appendix, as well with multiple invasions of the omentum. Furthermore, metastases of the periaortic (1/4) and right pelvic (1/6) lymph nodes were detected. Metastasis to the port-site was also diagnosed with pathological assessment of the 21x14 mm skin and subcutaneous tissue specimen which was excised from the right inguinal area 5 mm port-site. The patient had 6 courses of adjuvant chemotherapy consisting of cisplatinum (75 mg/m 2 ) and paclitaxel (175 mg/m 2 ) subsequent to the surgery. After the last course CA-125 levels were 32 U/mL. Thereafter patient was taken to the follow-up program and she had no signs of recurrence 12 months after the last adju vant chemotherapy course.
Case 2
A 66 year-old woman was referred with a complaint of abdominal distention. Her initial gynecological and transvaginal ultrasonographic examination revealed bilateral enlarged ovaries (right 7x6x5 cm, left 6x6x9 cm) with multiple cystic and solid lesions and intra-abdominal ascites. The CA-125 level was 954 U/mL and the other tumor markers were normal. The cytological analysis of the ascites revealed an adenocarcinoma. Therefore, a diagnostic laparoscopy was performed to evaluate operability of the patient as she had a frozen pelvis on the bimanual gynecological examination and massive ascites, bilaterally enlarged ovaries, multiple implants of the diaphragm, peritoneal and serosal surfaces were determined, and multiple biopsies were taken from the ovaries and peritoneal surfaces. The three ports used during the procedure were 10 mm at the umbilicus and 5 mm at the bilateral inguinal areas. The harvesting port was the left inguinal one. The pathological assessment revealed a serous papillary ovarian cancer and multiple metastases to the peritoneal and serosal surfaces. Subsequently, neoadjuvant chemotherapy comprising of cisplatinum (75 mg/m 2 ) and paclitaxel (175 mg/m 2 ) was given for 4 courses with 21 day intervals. The level of CA-125 was 160 U/mL after the last chemotherapy course. A paraumbilical, 3x2 cm diameter subcutaneous nodule was noticed at the 10 mm port site after the second neoadjuvant chemotherapy course, 28 days after the laparoscopic procedure. Neoadjuvant chemotherapy was continued and the patient underwent primary debulking surgery. Port-site metastasis was also excised and the residual tumor size was <1 cm. The pathological assessment revealed serous papillary adenocarcinoma of the ovary with invasion of bilateral ovarian surfaces, parametrium, serosal surfaces of tubes, uterus and appendix as well multiple invasions of the omentum. Furthermore, metastases to pelvic (2/4) lymph nodes were reported. Metastasis to the port-site was also diagnosed by pathological assessment (Fig. 1) . The patient had 6 courses of adjuvant chemotherapy consisting of cisplatinum (75 mg/m 2 ) and paclitaxel (175 mg/m 2 ) subsequent to the surgery. After the last course CA-125 levels www.ejgo.org 59
were 35 U/mL. Thereafter the patient was taken to the followup program and she had no signs of recurrence 6 months after the last adjuvant chemotherapy course.
DISCUSSION
Diagnostic laparoscopy has become a preferred technique to evaluate operability of ovarian cancers. But one of the major concerns of laparoscopy in ovarian cancers is the development of port-site metastasis. Port site metastasis after diagnostic laparoscopy during neoadjuvant chemotherapy is an extremely rare situation [11] . In the vast majority (71%) of the cases the metastasis was isolated to and diagnosed at the "manipulation port" which is described as the port whereby instruments for biopsies inserted or extraction of tumor biopsies were done [12] . The median time to development of port-site metastasis was calculated as 17 days (range, 4 to 730 days) [12] .
The potential risk factors for port-site metastasis are insufflation with carbon dioxide (tissue acidosis), high efflux of gas from the abdominal cavity through the space around the trocars (chimney effect), influence of local immune system, surgical technique, and the potential for contamination of the trocar site with viable tumor cells and presence of ascites [12, 13] . According to Wang et al. [14] presence of ascites is significantly associated with the early occurrence of portsite metastases. There are some recommended measures to prevent port-site metastasis which include using wound protectors, minimal tumor manipulation, avoiding CO 2 leaks and sudden desufflations, performing gasless laparoscopy, irrigation of ports with heparin or povidone-iodine solution before removal, excision of trocar sites and deliberate closure of all abdominal layers including the peritoneum, and early chemotherapy [9] . However, there is not enough evidence of effective prevention of port-site metastasis [9] . In Table 1 the two patients are summarized with risk factors for port-site metastasis.
Although there are reports about poor outcome with portsite metastasis during neoadjuvant chemotherapy in patients who have ascites, it has also reported that port-site metastasis do not affect the prognosis [8, 12, 13] . According to the study of van Dam et al. [8] , port-site metastasis during neoadjuvant chemotherapy does not have a significant impact on the outcome. However, according to the study of Huang et al. [13] , those patients who had port-site-metastasis that develop during chemotherapy have poor prognosis, and all died because of the cancer. The management of port-site metastases is primary excision of the tumor during debulking surgery. Despite the presence of ascites and occurrence during neoadjuvant chemotherapy, the treatment seems to be successful in our patients for the short duration of followup ( Table 1) .
The role of laparoscopy in ovarian malignancies is still a matter of debate. Although it has many benefits, there is a risk of port-site metastasis especially in advanced ovarian cancer patients who have ascites. Therefore, we should try to perform the preventive measures in practice as much as possible, and because of its possible poor prognosis we should start neoadjuvant chemotherapy course immediately. Anyhow, if port-site metastasis occurs the management should be local excision during debulking surgery. 
